Skip to main content

Voyager Therapeutics stock soars on Pfizer deal

Shares of Cambridge biotech Voyager Therapeutics Inc. are up more than 60% on the news that the company inked a $630 million licensing deal with Pfizer Inc.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.